Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1E | P49674 | 13/20 | 0.60 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.42 |
| ▸ | RIPK3 | Q9Y572 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3116569 | 0.88 | CSNK1E (0.74) | CSNK1ECSNK1DRIPK3 | |
| SCHEMBL3356106 | 0.88 | CSNK1E (0.56) | CSNK1ECSNK1DRIPK3HSD17B10PIM1 | |
| SCHEMBL3355880 | 0.86 | CSNK1E (0.81) | CSNK1ECSNK1DRIPK3 | |
| SCHEMBL3355873 | 0.86 | CSNK1E (0.81) | CSNK1ECSNK1DRIPK3 | |
| SCHEMBL15062742 | 0.86 | CSNK1E (0.54) | CSNK1ECSNK1DRIPK3HSD17B10PIM1 | |
| SCHEMBL3356197 | 0.86 | CSNK1E (0.81) | CSNK1ECSNK1DRIPK3PIM1 | |
| SCHEMBL3359820 | 0.85 | CSNK1E (0.53) | CSNK1ECSNK1DRIPK3HSD17B10PIM1 | |
| SCHEMBL3354235 | 0.85 | CSNK1E (0.53) | CSNK1ECSNK1DRIPK3HSD17B10PIM1 | |
| SCHEMBL3354776 | 0.85 | CSNK1E (0.55) | CSNK1ECSNK1DRIPK3 | |
| SCHEMBL3356959 | 0.85 | CSNK1E (0.68) | CSNK1ECSNK1DRIPK3HSD17B10PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9108971-B2 | 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]-pyridazine and derivatives thereof preparation and therapeutic application thereof | SANOFI (FR) | 2015-08-18 | — | — | US | claimed |
| US-20130245023-A1 | 6-CYCLOAMINO-3-(PYRIDAZIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE AND DERIVATIVES THEREOF PREPARATION AND THERAPEUTIC APPLICATION THEREOF | SANOFI (FR) | 2013-09-19 | — | — | US | claimed |
| EP-2178879-B1 | 6-CYCLOAMINO-S-(PYRIDAZIN-4-YL)IMIDAZO[1,2-B]-PYRIDAZINE AND DERIVATIVES THEREOF PREPARATION AND THERAPEUTIC APPLICATION THEREOF | SANOFI SA (FR) | 2013-07-03 | — | — | EP | claimed |
| US-8455491-B2 | 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]pyridazine and derivatives and pharmaceutical compositions comprising the same | SANOFI (FR) | 2013-06-04 | — | — | US | claimed |
| US-20100152157-A1 | 6-CYCLOAMINO-3-(PYRIDAZIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE AND DERIVATIVES THEREOF PREPARATION AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2010-06-17 | — | — | US | claimed |
| EP-2178879-A2 | 6-CYCLOAMINO-S-(PYRIDAZIN-4-YL)IMIDAZO[1,2-B]-PYRIDAZINE AND DERIVATIVES THEREOF PREPARATION AND THERAPEUTIC APPLICATION THEREOF | Sanofi-Aventis (FR) | 2010-04-28 | — | — | EP | claimed |
| WO-2009037394-A2 | 6-CYCLOAMINO-S-(PYRIDAZIN-4-YL)IMIDAZO[1,2-B]-PYRIDAZINE AND DERIVATIVES THEREOF PREPARATION AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2009-03-26 | — | — | WO | claimed |
| WO-2020249717-A1 | CASEIN KINASE 1 INHIBITORS FOR USE IN THE TREATMENT OF DISEASES RELATED TO DUX4 EXPRESSION SUCH AS MUSCULAR DYSTROPHY AND CANCER | Facio Intellectual Property B.V. (NL) | 2020-12-17 | — | — | WO | disclosed |
| US-9108971-B2 | 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]-pyridazine and derivatives thereof preparation and therapeutic application thereof | SANOFI (FR) | 2015-08-18 | — | — | US | disclosed |
| US-9108971-B2 | 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]-pyridazine and derivatives thereof preparation and therapeutic application thereof | SANOFI (FR) | 2015-08-18 | — | — | US | disclosed |
| US-9108971-B2 | 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]-pyridazine and derivatives thereof preparation and therapeutic application thereof | SANOFI (FR) | 2015-08-18 | — | — | US | disclosed |
| US-20130245023-A1 | 6-CYCLOAMINO-3-(PYRIDAZIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE AND DERIVATIVES THEREOF PREPARATION AND THERAPEUTIC APPLICATION THEREOF | SANOFI (FR) | 2013-09-19 | — | — | US | disclosed |
| US-20130245023-A1 | 6-CYCLOAMINO-3-(PYRIDAZIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE AND DERIVATIVES THEREOF PREPARATION AND THERAPEUTIC APPLICATION THEREOF | SANOFI (FR) | 2013-09-19 | — | — | US | disclosed |
| US-8455491-B2 | 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]pyridazine and derivatives and pharmaceutical compositions comprising the same | SANOFI (FR) | 2013-06-04 | — | — | US | disclosed |
| US-20100152157-A1 | 6-CYCLOAMINO-3-(PYRIDAZIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE AND DERIVATIVES THEREOF PREPARATION AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2010-06-17 | — | — | US | disclosed |
| US-20100152157-A1 | 6-CYCLOAMINO-3-(PYRIDAZIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE AND DERIVATIVES THEREOF PREPARATION AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2010-06-17 | — | — | US | disclosed |
| US-20100152157-A1 | 6-CYCLOAMINO-3-(PYRIDAZIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE AND DERIVATIVES THEREOF PREPARATION AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2010-06-17 | — | — | US | disclosed |
| EP-2178879-A2 | 6-CYCLOAMINO-S-(PYRIDAZIN-4-YL)IMIDAZO[1,2-B]-PYRIDAZINE AND DERIVATIVES THEREOF PREPARATION AND THERAPEUTIC APPLICATION THEREOF | Sanofi-Aventis (FR) | 2010-04-28 | — | — | EP | disclosed |
| WO-2009037394-A2 | 6-CYCLOAMINO-S-(PYRIDAZIN-4-YL)IMIDAZO[1,2-B]-PYRIDAZINE AND DERIVATIVES THEREOF PREPARATION AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2009-03-26 | — | — | WO | disclosed |
| WO-2009037394-A2 | 6-CYCLOAMINO-S-(PYRIDAZIN-4-YL)IMIDAZO[1,2-B]-PYRIDAZINE AND DERIVATIVES THEREOF PREPARATION AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130245023-A1 | 6-CYCLOAMINO-3-(PYRIDAZIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE AND DERIVATIVES THEREOF PREPARATION AND THERAPEUTIC APPLICATION THEREOF | TLR7, IFNAR1, CBR3 | CSNK1E 757/4885CSNK1D 732/4885RIPK3 3773/4885 |
| US-20100152157-A1 | 6-CYCLOAMINO-3-(PYRIDAZIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE AND DERIVATIVES THEREOF PREPARATION AND THERAPEUTIC APPLICATION THEREOF | IFNAR1, TLR7, CBR3 | CSNK1E 724/4885CSNK1D 690/4885RIPK3 3634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.